TY - JOUR
T1 - Health-related quality of life in adolescent patients with hepatitis C genotype 1 treated with Sofosbuvir and Ledipasvir
AU - Younossi, Zobair M.
AU - Stepanova, Maria
AU - Balistreri, William
AU - Schwarz, Kathleen
AU - Murray, Karen F.
AU - Rosenthal, Philip
AU - Bansal, Sanjay
AU - Hunt, Sharon
N1 - Funding Information:
This study was funded by Gilead Sciences.
Publisher Copyright:
Copyright © 2017 ESPGHAN and NASPGHAN.
PY - 2018/1/1
Y1 - 2018/1/1
N2 - Objective: The aim of the study was to assess the effect of treatment with ledipasvir/sofosbuvir (LDV/SOF) on the health-related quality of life (HRQL) of pediatric patients with chronic hepatitis C virus (HCV) infection. Methods: Adolescents (12-17 years) with HCV were treated with LDV/SOF (90/400mgdaily) for12weeks.HRQLwasassessedusingthePedsQLv4.0-SF15 completed by the children and caregivers before, during, and after treatment. Results: We included 100 adolescents with HCV genotype 1 infection (14.7±2.0 years, 1% known cirrhosis, 80% treatment-naïve, 97% sustained virologic response-12). At baseline, HRQL the caregiver- perceived HRQL scores were lower than adolescents' self-reported scores (by 6.7-7.9 points, all P<0.01). At the end of 12 weeks of treatment, however, the caregiver-reported HRQL scores showed a significant improvement (+all P<0.04), whereas the adolescents' self-reported scores did not change fromthe baseline.HRQLscores reported by caregivers remained higher than baseline (by+4.7-+7.5, P<0.01) through 12weeks after treatment, as did the adolescents' self-reportedEmotional Functioning scores (+4.3 from baseline, P=0.0009); observed improvements were sustained after 24 weeks of follow-up (all P<0.04).Multivariate analysis showed that, after adjustment for location, age, and sex, having a history of anxiety and panic disorders were consistent predictors of impaired HRQL in adolescents with HCV infection (P<0.05). Conclusions: Treatment of HCV in adolescents with LDV/SOF is associated with some improvement in HRQL. Caregivers' reports of HRQL in adolescents with HCV significantly increased with treatment and were similar to the adolescent self-reported HRQL after sustained virologic response-12.
AB - Objective: The aim of the study was to assess the effect of treatment with ledipasvir/sofosbuvir (LDV/SOF) on the health-related quality of life (HRQL) of pediatric patients with chronic hepatitis C virus (HCV) infection. Methods: Adolescents (12-17 years) with HCV were treated with LDV/SOF (90/400mgdaily) for12weeks.HRQLwasassessedusingthePedsQLv4.0-SF15 completed by the children and caregivers before, during, and after treatment. Results: We included 100 adolescents with HCV genotype 1 infection (14.7±2.0 years, 1% known cirrhosis, 80% treatment-naïve, 97% sustained virologic response-12). At baseline, HRQL the caregiver- perceived HRQL scores were lower than adolescents' self-reported scores (by 6.7-7.9 points, all P<0.01). At the end of 12 weeks of treatment, however, the caregiver-reported HRQL scores showed a significant improvement (+all P<0.04), whereas the adolescents' self-reported scores did not change fromthe baseline.HRQLscores reported by caregivers remained higher than baseline (by+4.7-+7.5, P<0.01) through 12weeks after treatment, as did the adolescents' self-reportedEmotional Functioning scores (+4.3 from baseline, P=0.0009); observed improvements were sustained after 24 weeks of follow-up (all P<0.04).Multivariate analysis showed that, after adjustment for location, age, and sex, having a history of anxiety and panic disorders were consistent predictors of impaired HRQL in adolescents with HCV infection (P<0.05). Conclusions: Treatment of HCV in adolescents with LDV/SOF is associated with some improvement in HRQL. Caregivers' reports of HRQL in adolescents with HCV significantly increased with treatment and were similar to the adolescent self-reported HRQL after sustained virologic response-12.
KW - Interferon
KW - Pediatric patients
KW - Quality of life
KW - Ribavirin
KW - School functioning
UR - http://www.scopus.com/inward/record.url?scp=85039710637&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85039710637&partnerID=8YFLogxK
U2 - 10.1097/MPG.0000000000001754
DO - 10.1097/MPG.0000000000001754
M3 - Article
C2 - 28957984
AN - SCOPUS:85039710637
SN - 0277-2116
VL - 66
SP - 112
EP - 116
JO - Journal of pediatric gastroenterology and nutrition
JF - Journal of pediatric gastroenterology and nutrition
IS - 1
ER -